MT1H
Overview
MT1H is a metallothionein family isoform involved in metal homeostasis and cellular stress responses. In HER2+ metastatic esophagogastric cancer, MT1H expression was identified by single-cell RNA-seq as part of a resistance transcriptional program to trastuzumab-based therapy.
Alterations observed in the corpus
- MT1H expression associated with trastuzumab + chemotherapy resistance by scRNA-seq in HER2+ esophagogastric cancer (EGC) escape lesions; identified alongside MT1E, MT2A, and MSMB as candidate future therapeutic targets PMID:37406106.
Cancer types (linked)
- Esophagogastric cancer (HER2+) — MT1H expressed in resistance subpopulations at progression on trastuzumab-based therapy PMID:37406106.
Co-occurrence and mutual exclusivity
- Co-expressed with MT1E, MT2A, and MSMB in trastuzumab-resistant HER2+ EGC escape lesions PMID:37406106.
Therapeutic relevance
- MT1H is a candidate future therapeutic target; requires orthogonal preclinical validation PMID:37406106.
Open questions
- The functional mechanism by which MT1H contributes to trastuzumab resistance is not experimentally established.
Sources
This page was processed by crosslinker on 2026-05-04.